ASMS | Jotup

Volaris Reports October 2023 Traffic Results: 2% YoY Demand Growth with an 89% Load Factor

Retrieved on:

月曜日, 11月 6, 2023

Yoy, MEXICO, NYSE, Volaris, Category 1, CITY, BMV, VLRS, ULCC, Aircraft, Airline, ASMS

de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central, and South America, reports its October 2023 preliminary traffic results.

Key Points:

de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central, and South America, reports its October 2023 preliminary traffic results.
In October 2023, Volaris’ capacity (measured in ASMs) increased by 2.4% year-over-year, while demand (measured in RPMs) increased by 2.2%; the result was a load factor decrease of 0.2 pp YoY to 89.5%.
Demand (measured in RPMs) in the Mexican domestic market decreased by 5.2%, while demand increased by 20.1% in the international market.
Demand remains strong in both domestic and international markets, driving the domestic load factor to a new October record high.

Frontier Airlines Reports Third Quarter 2023 Financial Results

Retrieved on:

木曜日, 10月 26, 2023

Environment, Airbus A320neo family, Vancouver's greenest city action plan, ASMS, Security (finance), Risk, GAAP, Airline, Frontier

During the third quarter of 2023, Frontier generated 103 ASMs per gallon.

Key Points:

During the third quarter of 2023, Frontier generated 103 ASMs per gallon.
Frontier took delivery of eight A321neo aircraft during the third quarter of 2023, of which five were direct leases, increasing the proportion of the fleet comprised of the more fuel-efficient A320neo family aircraft to 77 percent as of September 30, 2023, the highest of all major U.S. carriers.
Fourth quarter capacity is expected to grow by 12 percent to 14 percent over the comparable 2022 quarter.
The current forward guidance estimates for the fourth quarter 2023 are presented in the following table:

Frontier Airlines Releases 2022 Environmental, Social, and Governance Report

Retrieved on:

木曜日, 10月 26, 2023

Air travel, Ethics, ESG, Frontier, Sky, Frontier Airlines, ASMS, Risk management, Culture, ULCC, Philosophy, Ultra, Airline, Management, Social

DENVER, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultra-low fare carrier Frontier Airlines ( NASDAQ: ULCC ) today released its 2022 Environmental, Social, and Governance (ESG) Report.

Key Points:

DENVER, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultra-low fare carrier Frontier Airlines ( NASDAQ: ULCC ) today released its 2022 Environmental, Social, and Governance (ESG) Report.
The in-depth review highlights Frontier’s robust commitment to responsible environmental stewardship, team member diversity and well-being, community engagement and governance.
“Every one of the 20,000 members of Team Frontier — which includes Frontier employees and vendors — are essential to delivering Low Fares Done Right,” said Biffle.
* Measured by ASMs per fuel gallon consumed over the twelve months ended December 31, 2022; other airline average calculated as weighted average of the nine major U.S. airlines.

Volaris Reports Financial Results for the Third Quarter 2023

Retrieved on:

水曜日, 10月 25, 2023

Sale, LTM, CASM, ASMS, ADS, Investment, Aircraft, EBITDAR, Bank, Video game, Airline, Textile

Total operating revenues in the quarter were $848 million, a 10% increase driven by robust demand across our network and a rise in ancillary revenue per passenger.

Key Points:

Total operating revenues in the quarter were $848 million, a 10% increase driven by robust demand across our network and a rise in ancillary revenue per passenger.
The load factor for the quarter reached 86.4%, representing an increase of 0.7 percentage points compared to the same period in 2022.
Total operating expenses in the quarter were $809 million, representing 95% of total operating revenue, remaining consistent with the same quarter in 2022.
Net debt-to-LTM EBITDAR6 ratio stood at 3.5 times, in line with the second quarter of 2023 and 0.4 times lower when compared to the end of 2022.

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

Retrieved on:

月曜日, 10月 9, 2023

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy.

Key Points:

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy.
Importantly, the efficacy and safety findings of this clinical trial supported the further clinical development in epilepsy of XEN1101, which is currently being evaluated in Phase 3 clinical trials in patients with focal onset seizures (FOS) and primary generalized tonic-clonic seizures.
Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to report that the peer-reviewed results from our Phase 2b X-TOLE study of XEN1101 in adults with focal epilepsy have been published in the prestigious JAMA Neurology journal.
The article entitled “Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy A Phase 2b Randomized Clinical Trial” was posted today on the JAMA Neurology website .

Allotrope Foundation Releases a Vendor Agnostic and an Industry Interoperable Data Model for Laboratory Walk-up Liquid Chromatography/Mass Spectrometry Instrumentation

Retrieved on:

金曜日, 9月 8, 2023

WASHINGTON, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Allotrope Foundation, an international consortium of chemical & life sciences organizations, is excited to release a vendor agnostic and an industry interoperable data model for laboratory Walk-up Liquid Chromatography/Mass Spectrometry (LC/MS) instrumentation. The technique provides users a method of submitting samples to LC/MS instruments for automated data acquisition and analysis without the need for prior scheduling. Since it allows researchers to quickly and easily obtain data, it is commonly employed in research laboratories, industrial settings, and academic institutions for a wide range of applications including during drug discovery and development, food and beverage analysis, as well as environmental samples analysis. LC/MS combines the separation capabilities of liquid chromatography with the sensitive detection and identification capabilities of mass spectrometry. Via Walk-up LC/MS a researcher can rapidly obtain information about a sample's composition, structure, and quantity.

Key Points:

WASHINGTON, Sept. 7, 2023 /PRNewswire-PRWeb/ -- Allotrope Foundation, an international consortium of chemical & life sciences organizations, is excited to release a vendor agnostic and an industry interoperable data model for laboratory Walk-up Liquid Chromatography/Mass Spectrometry (LC/MS) instrumentation.
LC/MS combines the separation capabilities of liquid chromatography with the sensitive detection and identification capabilities of mass spectrometry.
The Walkup LC/MS data model was developed by the Allotrope Foundation's Mass Spectrometry Working Group, comprised of subject matter experts from Allotrope Foundation and Allotrope Partner Network (APN) member organizations.
Working together, these interoperable data models promote collaboration, efficiency, and data quality in research and accelerate advancement in drug discovery.

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

Retrieved on:

月曜日, 9月 4, 2023

VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023.

Key Points:

Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales
VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023.
Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “The IEC meeting in Dublin provides us with another key opportunity to connect with leading epileptologists and showcase our XEN1101 Phase 3 epilepsy program, which includes our ongoing X-TOLE2, X-TOLE3, and X-ACKT clinical trials in focal onset seizures and primary generalized tonic-clonic seizures, respectively.
The SFG consisted of 29 patients (approximately 10.5% of those enrolled in the OLE).
As a clinician, it is encouraging to see these QoL data, such as the improvements seen across all patients in Medication Effects, as this suggests that patients may benefit from XEN1101, perceiving it to be efficacious and generally well tolerated.

Photonis Expands Market-Leading Mass Spectrometry Detection Technology

Retrieved on:

火曜日, 5月 23, 2023

Microchannel plate detector, American Society for Mass Spectrometry, Partnership, ASMS, Mass spectrometry, A300, George R. Brown Convention Center, Quality of life, AC, MS, Research and development, Development, Investment, Research, Microchannel, Society, Conference, Bipolar, Medical imaging

Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.

Key Points:

Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.
At this occasion, Photonis, the leaders in Time-of-Flight (TOF) detection technologies, will showcase their latest advancements in TOF detection with additions to their existing detector platforms - the APTOF and BPTOF Series.
Ulrich Laupper, President and General Manager of Photonis' Ultimate Detection Business Unit: "We are excited to introduce the next generation of Time-of-Flight detection technology at this year's ASMS Conference.
The APTOF A300 and BPTOF B380 provide mass spectrometry instrument manufacturers an unmatched cost-of-ownership value proposition.

Quantum-Si Reports Second Quarter 2023 Financial Results

Retrieved on:

月曜日, 8月 7, 2023

Operating expenses were $27.0 million in the second quarter of 2023, compared to $30.2 million in the second quarter of 2022.

Key Points:

Operating expenses were $27.0 million in the second quarter of 2023, compared to $30.2 million in the second quarter of 2022.
Net loss was $25.6 million in the second quarter of 2023, compared to a net loss of $32.4 million in the second quarter of 2022.
Adjusted EBITDA was negative $22.9 million in the second quarter of 2023, compared to negative $25.8 million in the second quarter of 2022.
Quantum-Si will host a conference call to discuss its second quarter 2023 financial results on Monday, August 7, 2023, at 8:30 AM Eastern Time.

Sun Country Airlines Reports Second Quarter 2023 Results

Retrieved on:

木曜日, 8月 3, 2023

Sun Country Airlines, Amazon, CASM, Growth, Travel, EBITDA, GAAP, ASMS, Adjustment, Airline

MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sun Country Airlines Holdings, Inc. (“Sun Country Airlines,” “Sun Country,” the “Company”) (NASDAQ: SNCY) today reported financial results for its second quarter ended June 30, 2023.

Key Points:

For the second quarter of 2023, the Company reported total revenue of $261 million, which was 19.2% more than the second quarter of 2022.
The second quarter 2023 average total fare of $177 exceeded second quarter 2022 by 2.7% and included strong average ancillary revenue per passenger of $66.
In the second quarter of 2023, cargo revenue was $25 million, an 18.1% increase versus the second quarter of 2022.
Adjusted CASM(4) in the second quarter increased 10.4% versus the second quarter 2022 due to a decrease in daily aircraft utilization of 9.5% for the same period.